Reconciling ASPP-p53 binding mode discrepancies through an ensemble binding framework that bridges crystallography and NMR data

PLoS Comput Biol. 2024 Feb 7;20(2):e1011519. doi: 10.1371/journal.pcbi.1011519. eCollection 2024 Feb.

Abstract

ASPP2 and iASPP bind to p53 through their conserved ANK-SH3 domains to respectively promote and inhibit p53-dependent cell apoptosis. While crystallography has indicated that these two proteins employ distinct surfaces of their ANK-SH3 domains to bind to p53, solution NMR data has suggested similar surfaces. In this study, we employed multi-scale molecular dynamics (MD) simulations combined with free energy calculations to reconcile the discrepancy in the binding modes. We demonstrated that the binding mode based solely on a single crystal structure does not enable iASPP's RT loop to engage with p53's C-terminal linker-a verified interaction. Instead, an ensemble of simulated iASPP-p53 complexes facilitates this interaction. We showed that the ensemble-average inter-protein contacting residues and NMR-detected interfacial residues qualitatively overlap on ASPP proteins, and the ensemble-average binding free energies better match experimental KD values compared to single crystallgarphy-determined binding mode. For iASPP, the sampled ensemble complexes can be grouped into two classes, resembling the binding modes determined by crystallography and solution NMR. We thus propose that crystal packing shifts the equilibrium of binding modes towards the crystallography-determined one. Lastly, we showed that the ensemble binding complexes are sensitive to p53's intrinsically disordered regions (IDRs), attesting to experimental observations that these IDRs contribute to biological functions. Our results provide a dynamic and ensemble perspective for scrutinizing these important cancer-related protein-protein interactions (PPIs).

MeSH terms

  • Apoptosis
  • Apoptosis Regulatory Proteins* / chemistry
  • Crystallography
  • Protein Binding
  • Tumor Suppressor Protein p53* / chemistry

Substances

  • Apoptosis Regulatory Proteins
  • Tumor Suppressor Protein p53

Grants and funding

This work was supported by the Harbin Medical University high-level introduction of talent research start-up fund (No.310212000109 to B.S., No.31011210004 to M.Z), the Provincial Basic Research Fund for Universities (No. 2023-KYYWF-0265 to B.S) and the National Science Foundation (No. 22002096 to M.Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.